EPO revokes Arbutus' European patent EP 2279254; company plans appeal

Arbutus Biopharma Corp

EPO Board of Appeal revoked Arbutus' European patent EP 2279254 on Jan 15, 2026; verbal decision without reasons; written decision expected in months.
Opposition originally filed by Moderna affiliates and Merck in April 2018; two prior EPO decisions had upheld amended patent.
Company plans to petition EPO Enlarged Board of Appeal upon receipt of written decision; decision affects cases vs Moderna in Switzerland and UPC Case UPC_CFI_191/2025.
Decision does not impact litigations in US, Japan, Canada, other UPC case (UPC_CFI_192/2025), or cases against Pfizer/BioNTech.
Company notes added-matter standard used by EPO does not apply in US or other jurisdictions; no impact on other patent cases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.